Utidelone for advanced ovarian, fallopian tube, or peritoneal cancer
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new oral medication, utidelone, for people with advanced ovarian, fallopian tube, or primary peritoneal cancer that has come back after platinum-based chemotherapy. The goal is to see if utidelone can help control the cancer and potentially slow its growth.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You must be at least 18 years old and diagnosed with advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer.
- Your cancer must have grown or returned within 6 months after your last platinum-based treatment (like carboplatin or cisplatin).
- You must have at least one tumor that can be measured on a scan.
- You must have had at least 1 but no more than 3 previous systemic treatments (not counting initial chemo as first-line unless it didn't work).
- You should be generally active (able to do light activities) and have adequate kidney, liver, and blood cell counts.
- You must not be pregnant, breastfeeding, or planning to become pregnant during the study.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new drug called utidelone for people with advanced solid tumors that have not responded to standard treatments. It may help shrink tumors or slow their growth.
This trial tests an investigational drug called TORL-1-23 for people with ovarian cancer that has stopped responding to platinum chemotherapy. It aims to see if the drug can help shrink or control the cancer.
This study tests a new investigational drug, raludotatug deruxtecan (R-DXd), given alone or with another drug called bevacizumab, as maintenance treatment after second-line platinum-based chemotherapy for recurrent ovarian cancer. The goal is to keep the cancer from growing longer.
This trial tests a combination of two drugs (utidelone and fruquintinib) for ovarian cancer that has stopped responding to platinum-based chemotherapy. The goal is to see if this combo can shrink tumors or slow the cancer's growth.
This trial tests a new chemotherapy drug called utidelone, given before surgery for early high-risk or locally advanced breast cancer. The goal is to see if this drug can shrink tumors and improve outcomes. It may be a treatment option for people who meet the specific criteria.
This trial compares utidelone with docetaxel in people with HER2-negative advanced or metastatic breast cancer. It aims to see which treatment works better and is safer for controlling the cancer and helping patients live longer.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.